Q-omics provides the consensus-scored MIR4632 profile across patient tissues and cancer cell-line models. MIR4632 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, MIR4632 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, MIR4632 RNA expression shows 7,336 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight STAD, KIRC, and ESCA as cancer lineages where MIR4632 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4632 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4632 survival associations across molecular data types. MIR4632 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4632 RNA expression–survival associations across cancer types. High MIR4632 expression shows unfavorable associations in DLBC, CESC, OV, LUSC and THCA, but favorable associations in STAD. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for MIR4632 RNA expression.
This table summarizes MIR4632 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4632. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4632 shows lower tumor expression in LUSC and higher tumor expression in KIRC. The KIRC box plot shows higher MIR4632 RNA expression in tumor versus normal tissue (log2 FC = +0.129, t-test p = .030).
This table shows molecular features associated with MIR4632 in patient tissues and cancer cell lines. In patient samples, MIR4632 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
